Combination of &aplha;-blocker and 5&aplha;-reductase inhibitor for treatment of benign prostatic hyperplasia
Clinical and Investigative Medicine Oct 30, 2017
Kang D, et al. - A comparative scrutiny was performed of an α-blocker monotherapy alone with a combination of α-blocker plus 5α-reductase in treatment of benign prostatic hyperplasia (BPH). The yielded data pointed towards the combined &aplha;-blocker plus 5&aplha;-reductase therapy being more beneficial in treating benign prostatic hyperplasia than the &aplha;-blocker monotherapy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
